Asklid D, Segelman J, Gedda C, Hjern F, Pekkari K, Gustafsson U O
Department of Surgery, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Surgery Ersta Hospital, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Eur J Surg Oncol. 2017 Aug;43(8):1433-1439. doi: 10.1016/j.ejso.2017.04.003. Epub 2017 May 3.
Restricted perioperative fluid therapy is one of several interventions in the enhanced recovery after surgery (ERAS) protocol, designed to reduce morbidity and hospital stay after surgery. The impact of this single intervention on short and long term outcome after colorectal surgery is unknown.
This cohort study includes all consecutive patients operated with abdominal resection of colorectal cancer 2002-2007 at Ersta Hospital, Stockholm, Sweden. All patients were treated within an ERAS protocol and registered in the ERAS-database. Compliance to interventions in the ERAS protocol was analysed. The impact of a restrictive perioperative fluid therapy (≤3000 ml on the day of surgery) protocol on short-term outcomes as well as 5-year survival was assessed with multivariable analysis adjusted for confounding factors.
Nine hundred and eleven patients were included. Patients receiving ≤3000 ml of intravenous fluids on the day of surgery had a lower risk of complications OR 0.44 (95% C I 0.28-0.71), symptoms delaying discharge OR 0.47(95% C I 0.32-0.70) and shorter length of stay compared with patients receiving >3000 ml. In cox regression analysis, the risk of cancer specific death was reduced with 55% HR 0.45(95% C I 0.25-0.81) for patients receiving ≤ 3000 ml compared with patients receiving >3000 ml.
A restrictive compared with a non-restrictive perioperative fluid therapy on the day of surgery may be associated with lower short-term complication rates, faster recovery, shorter length of stay and improved 5-year survival.
围手术期限制性液体治疗是术后加速康复(ERAS)方案中的几种干预措施之一,旨在降低术后发病率和缩短住院时间。这种单一干预措施对结直肠癌手术后短期和长期结局的影响尚不清楚。
这项队列研究纳入了2002年至2007年在瑞典斯德哥尔摩埃斯塔医院接受结直肠癌腹部切除术的所有连续患者。所有患者均按照ERAS方案进行治疗,并在ERAS数据库中进行登记。分析了对ERAS方案干预措施的依从性。采用多变量分析评估围手术期限制性液体治疗(手术当天≤3000毫升)方案对短期结局以及5年生存率的影响,并对混杂因素进行了校正。
共纳入911例患者。与接受超过3000毫升静脉输液的患者相比,手术当天接受≤3000毫升静脉输液的患者发生并发症的风险较低,OR为0.44(95%CI 0.28 - 0.71),延迟出院的症状发生率较低,OR为0.47(95%CI 0.32 - 0.70),住院时间更短。在Cox回归分析中,与接受超过3000毫升的患者相比,接受≤3000毫升的患者癌症特异性死亡风险降低了55%,HR为0.45(95%CI 0.25 - 0.81)。
与手术当天非限制性围手术期液体治疗相比,限制性液体治疗可能与较低的短期并发症发生率、更快的恢复、更短的住院时间和改善的5年生存率相关。